Diffuse large B-cell lymphoma: open trials in Canada

16 open trials have a site in Canada. Registry data; only the trial team decides who can take part.

NCT07188558
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Trial Treatment · Phase 3 · Lyell Immunopharma, Inc.
Princess Margaret Cancer Centre, Toronto
Registry updated 2026-11-04
NCT05139017
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Trial Treatment · Phase 2/3 · Merck Sharp & Dohme LLC
Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0200), Toronto
Registry updated 2026-11-03
NCT05365659
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
Trial Treatment · Phase 1 · Iksuda Therapeutics Ltd.
Jewish General Hospital, Montreal
Registry updated 2026-11-03
NCT06395103
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Trial Treatment · Phase 1/2 · Merck Sharp & Dohme LLC
Alberta Children's Hospital ( Site 1227), Calgary · McGill University Health Centre-Pediatric HematologyOncology ( Site 1223), Montreal · The Hospital for Sick Children ( Site 1225), Toronto
Registry updated 2026-10-30
NCT06500273
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Trial Treatment · Phase 2 · Allogene Therapeutics
Arthur Je Child Comprehensive Cancer Centre, Calgary · Queen Elizabeth II, Health Sciences Centre, Halifax · CHUM - University of Montreal Hospital Centre, Montreal · Centre Intégré Universitaire de Sante et Services Sociaux de L'Est de I'lle de Montreal / installation Hopital Maisonneuve-Rosemont, Montreal · Hopital de L'enfant Jesus, Québec · Princess Margaret Cancer Centre - University Health Network, Toronto
Registry updated 2026-10-30
NCT06717347
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
Cross Cancer Institute ( Site 0205), Edmonton · Queen Elizabeth II Health Sciences Centre ( Site 0207), Halifax · Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0208), Hamilton · Lakeridge Health - The R.S. McLaughlin Durham Regional Cancer Centre (MDRCC) ( Site 0206), Oshawa · Sunnybrook Research Institute ( Site 0204), Toronto
Registry updated 2026-10-21
NCT06208735
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
Trial Treatment · Phase 1 · British Columbia Cancer Agency
Alberta Children's Hospital, Calgary · Arthur J.E. Child Comprehensive Cancer Centre, Calgary · The Ottawa Hospital - General Campus, Ottawa · Princess Margaret Cancer Centre, Toronto · The Hospital for Sick Children, Toronto · BC Children ' s Hospital, Vancouver · Vancouver General Hospital, Vancouver
Registry updated 2026-10-14
NCT06806033
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
Trial Treatment · Phase 2 · Hoffmann-La Roche
Arthur J.E. Child Comprehensive Cancer Center, Calgary · CancerCare Manitoba (CCMB), Winnipeg
Registry updated 2026-10-09
NCT05006716
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Trial Treatment · Phase 1/2 · BeOne Medicines
Arthur Je Child Comprehensive Cancer Centre, Calgary · Cross Cancer Institute, Edmonton · Chu de Quebec Universite Laval, Hopital de Lenfant Jesus, Centre Integre de Cancerologie (Cic), Québec · Princess Margaret Cancer Centre, Toronto · British Columbia Cancer Agency the Vancouver Centre, Vancouver
Registry updated 2026-10-05
NCT06224309
Preliminary Assessment of [18F]BL40 in PET/CT Scans
Research · British Columbia Cancer Agency
BC Cancer, Vancouver
Registry updated 2026-10-01
NCT04094311
Study of Out of Specification for Tisagenlecleucel
Trial Treatment · Phase 3 · Novartis Pharmaceuticals
Hamilton · Montreal · Ottawa · Québec · Toronto
Registry updated 2026-09-15
NCT04792489
DALY II USA/ MB-CART2019.1 for DLBCL
Trial Treatment · Phase 2 · Miltenyi Biomedicine GmbH
University of Alberta - Cross Cancer Institute, Edmonton · Princess Margaret Cancer Centre, Toronto
Registry updated 2026-07-13
NCT06050694
Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)
Trial Treatment · Phase 2 · University Health Network, Toronto
Jewish General Hospital, Montreal · Princess Margaret Cancer Centre, Toronto
Registry updated 2026-04-24
NCT06830759
Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma
Research · AbbVie
Cross Cancer Institute /ID# 271504, Edmonton · Health Sciences North /ID# 274738, Greater Sudbury · Kingston General Hospital /ID# 272061, Kingston · The Moncton Hospital /ID# 277230, Moncton · Eastern Health - General Hospital /ID# 272062, St. John's
Registry updated 2026-02-17
NCT05950802
Optimizing lymphoDepletion to Improve Outcomes In Patients Receiving Cell Therapy With Yescarta
Trial Treatment · Phase 1 · University Health Network, Toronto
Princess Margaret Cancer Centre, Toronto
Registry updated 2025-12-08
NCT04920617
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Trial Treatment · Phase 2 · ImmunoVaccine Technologies, Inc. (IMV Inc.)
Saskatoon Cancer Center, Saskatoon
Registry updated 2023-04-07

All Diffuse large B-cell lymphoma trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error